Previous Close | $340.07 |
Intrinsic Value | $1,468.74 |
Upside potential | +332% |
Data is not available at this time.
Elevance Health Inc. operates as a leading health benefits company in the U.S., primarily serving commercial, Medicaid, Medicare, and individual markets. The company generates revenue through premium-based health insurance plans, administrative services, and pharmacy benefit management. Its diversified portfolio includes medical, dental, vision, and behavioral health services, positioning it as a comprehensive healthcare solutions provider. Elevance Health leverages scale and data analytics to optimize care delivery and cost efficiency, reinforcing its competitive edge in a highly regulated and competitive industry. The company’s integrated model combines insurance with care delivery, enabling it to capture value across the healthcare continuum. Its strong brand recognition and strategic partnerships with providers enhance its ability to attract and retain members, solidifying its market leadership. Elevance Health’s focus on value-based care and digital health innovations further differentiates it from peers, aligning with industry shifts toward preventive and personalized healthcare.
Elevance Health reported $176.8 billion in revenue for FY 2024, reflecting its substantial scale in the health benefits sector. Net income stood at $6.0 billion, with diluted EPS of $25.68, indicating robust profitability. Operating cash flow of $5.8 billion underscores efficient cash generation, while capital expenditures of $1.3 billion suggest disciplined reinvestment in growth and operational capabilities.
The company’s earnings power is evident in its ability to sustain high revenue and net income levels, supported by a diversified revenue base. Capital efficiency is demonstrated by its strong operating cash flow relative to capital expenditures, enabling strategic investments and shareholder returns. The diluted EPS of $25.68 highlights effective earnings distribution across its 232.9 million outstanding shares.
Elevance Health maintains a solid balance sheet with $8.3 billion in cash and equivalents, providing liquidity for operations and strategic initiatives. Total debt of $31.2 billion is manageable given its cash flow generation and scale. The company’s financial health is further supported by its ability to service debt and fund growth without compromising stability.
Growth trends are underpinned by Elevance Health’s expanding membership and focus on value-based care. The company’s dividend policy, with a $6.48 per share payout, reflects its commitment to returning capital to shareholders while retaining funds for reinvestment. This balanced approach supports both growth and income-oriented investors.
Elevance Health’s valuation reflects its leadership position and consistent financial performance. Market expectations are likely anchored on its ability to navigate regulatory changes and capitalize on healthcare industry trends, such as digital transformation and preventive care. The company’s scale and profitability justify its premium valuation relative to peers.
Strategic advantages include Elevance Health’s integrated care model, data-driven insights, and strong provider networks. The outlook remains positive, driven by demographic tailwinds, healthcare demand growth, and innovation in care delivery. The company is well-positioned to sustain its market leadership and deliver long-term value to stakeholders.
Company filings, investor presentations, Bloomberg
show cash flow forecast
Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |